Top Markets
#1 Islamic Coin Islamic Coin +158.25%
#2 Glidr Glidr +58.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#4 Cryptopia Cryptopia +9.96%
#5 Pons Pons +7.79%
#6 Movement Movement +7.49%
#7 Victoria VR Victoria VR +7.22%
#8 龙虾 (Lobster) 龙虾 (Lobster) +6.47%
#9 COTI COTI +5.40%
#10 DMT-NAT DMT-NAT +5.17%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Kedudukan dalam Saham #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Harga Saham
$0.00023723
Disegerakkan terakhir: 2024-08-26
Modal Pasaran
$1.41K
Perubahan (1 hari)
111.67%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Pharnext S.A. (ALPHA)

Kategori

Healthcare
Nisbah P/E bagi Pharnext S.A. (ALPHA)
Nisbah P/E pada August 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Pharnext S.A., nisbah P/E semasa (TTM) ialah 0.00. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -258.45M.
Sejarah nisbah P/E bagi Pharnext S.A. dari 2012 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 0.00 -100.00%
2023 -0.03 -100.00%
2022 -258.45M -100.00%
2021 -10.818T -96.16%
2020 -281.589T -36.98%
2019 -446.809T -50.70%
2018 -906.363T 15.42%
2017 -785.292T -19.50%
2016 -975.560T -43.41%
2015 -1.72Qa -2.39%
2014 -1.77Qa -13.13%
2013 -2.03Qa 0.00%
2012 0.00 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.